FDA
-
-
-
-
-
-
-
Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights
-
-
-
-
-
-
-
Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights
-
-
-
-
-
-
-
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia
-
-
-
-
-
-
-
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
-
-
-
-
-
-
-
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
-
-
-
-
-
-
-
Lexeo Therapeutics (LXEO) Granted FDA Fast Track Designation for LX2006
-
-
-
-
-
-
328,143 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

